Heart Test Laboratories Inc. Common Stock (HSCS) - Net Assets
Based on the latest financial reports, Heart Test Laboratories Inc. Common Stock (HSCS) has net assets worth $226.06K USD as of April 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.26 Million) and total liabilities ($5.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. For live market cap and overall valuation, see market value of Heart Test Laboratories Inc. Common Stoc.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $226.06K |
| % of Total Assets | 4.3% |
| Annual Growth Rate | 199.2% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 47360.48 |
Heart Test Laboratories Inc. Common Stock - Net Assets Trend (2020–2026)
This chart illustrates how Heart Test Laboratories Inc. Common Stock's net assets have evolved over time, based on quarterly financial data.
Annual Net Assets for Heart Test Laboratories Inc. Common Stock (2020–2026)
The table below shows the annual net assets of Heart Test Laboratories Inc. Common Stock from 2020 to 2026. See HSCS equity financing ratio to measure how much of total assets are equity-financed.
| Year | Net Assets | Change |
|---|---|---|
| 2026-04-30 | $226.06 Million | +110081.26% |
| 2025-04-30 | $205.17K | -97.20% |
| 2024-04-30 | $7.32 Million | +3073.75% |
| 2023-04-30 | $230.56K | +103.81% |
| 2022-04-30 | $-6.06 Million | -217.13% |
| 2021-04-30 | $-1.91 Million | -705.16% |
| 2020-04-30 | $315.55K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Heart Test Laboratories Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8522238752200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.19 Million | 1.41% |
| Other Components | $85.49 Billion | 37907.59% |
| Total Equity | $225.53 Million | 100.00% |
Heart Test Laboratories Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Heart Test Laboratories Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Coloured Ties Capital Inc
V:TIE
|
$7.88 Million |
|
HUIJING HLDG.CO.LTD HD-01
F:3XU
|
$7.88 Million |
|
J-Long Group Limited
NASDAQ:JL
|
$7.88 Million |
|
Resources & Energy Group Ltd
AU:REZ
|
$7.89 Million |
|
CNS Pharmaceuticals Inc
NASDAQ:CNSP
|
$7.86 Million |
|
Immuron Ltd
AU:IMC
|
$7.86 Million |
|
XPS Pensions Group PLC
LSE:XPS
|
$7.86 Million |
|
Emerson Radio Corporation
NYSE MKT:MSN
|
$7.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Heart Test Laboratories Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 205,171 to 225,527,000, a change of 225,321,829 (109821.5%).
- Net loss of 9,141,875 reduced equity.
- New share issuances of 5,722,046 increased equity.
- Other factors increased equity by 228,741,658.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.14 Million | -4.05% |
| Share Issuances | $5.72 Million | +2.54% |
| Other Changes | $228.74 Million | +101.43% |
| Total Change | $- | 109821.48% |
Book Value vs Market Value Analysis
This analysis compares Heart Test Laboratories Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.29x to 0.03x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-04-30 | $9.52 | $2.80 | x |
| 2021-04-30 | $-57.63 | $2.80 | x |
| 2022-04-30 | $-182.46 | $2.80 | x |
| 2023-04-30 | $2.90 | $2.80 | x |
| 2024-04-30 | $20.76 | $2.80 | x |
| 2025-04-30 | $0.22 | $2.80 | x |
| 2026-04-30 | $85.90 | $2.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Heart Test Laboratories Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -211666.47%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 23.34x
- Recent ROE (-4.05%) is above the historical average (-1190.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -1207.77% | -5937.99% | 0.03x | 6.20x | $-3.84 Million |
| 2021 | 0.00% | -9577.29% | 0.01x | 0.00x | $-2.26 Million |
| 2022 | 0.00% | -33592.57% | 0.01x | 0.00x | $-4.22 Million |
| 2023 | -2756.06% | -123384.27% | 0.00x | 14.26x | $-6.38 Million |
| 2024 | -90.27% | -35511.87% | 0.00x | 1.30x | $-7.34 Million |
| 2025 | -4272.16% | -201499.52% | 0.00x | 20.58x | $-8.79 Million |
| 2026 | -4.05% | -211666.47% | 0.00x | 23.34x | $-31.69 Million |
Industry Comparison
This section compares Heart Test Laboratories Inc. Common Stock's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $950,974,451
- Average return on equity (ROE) among peers: -69.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Heart Test Laboratories Inc. Common Stock (HSCS) | $226.06K | -1207.77% | 22.28x | $7.88 Million |
| Abbott Laboratories (ABT) | $7.43 Billion | 32.93% | 0.95x | $196.11 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $14.41 Million |
| Aethlon Medical Inc (AEMD) | $5.77 Million | -211.71% | 0.43x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $762.44 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $5.69 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $2.07 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $2.86 Million |
| Artivion Inc (AORT) | $24.90 Million | 15.66% | 0.41x | $1.16 Billion |
| Apyx Medical Inc (APYX) | $6.01 Million | -36.31% | 0.22x | $131.43 Million |
About Heart Test Laboratories Inc. Common Stock
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related… Read more